1.72
price down icon9.95%   -0.19
pre-market  Pre-market:  1.80   0.08   +4.65%
loading
Prime Medicine Inc stock is traded at $1.72, with a volume of 2.03M. It is down -9.95% in the last 24 hours and down -33.72% over the past month. Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
See More
Previous Close:
$1.91
Open:
$1.91
24h Volume:
2.03M
Relative Volume:
1.83
Market Cap:
$225.60M
Revenue:
-
Net Income/Loss:
$-217.44M
P/E Ratio:
-0.7926
EPS:
-2.17
Net Cash Flow:
$-205.20M
1W Performance:
-25.22%
1M Performance:
-33.72%
6M Performance:
-57.95%
1Y Performance:
-78.31%
1-Day Range:
Value
$1.71
$1.96
1-Week Range:
Value
$1.71
$2.47
52-Week Range:
Value
$1.71
$8.27

Prime Medicine Inc Stock (PRME) Company Profile

Name
Name
Prime Medicine Inc
Name
Phone
617-465-0013
Name
Address
60 FIRST ST., CAMBRIDGE
Name
Employee
214
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
PRME's Discussions on Twitter

Compare PRME with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
PRME
Prime Medicine Inc
1.72 225.60M 0 -217.44M -205.20M -2.17
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
502.92 129.14B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
680.61 74.41B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
581.21 35.31B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.75 31.30B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.57 27.35B 3.32B -860.46M -1.04B -8.32

Prime Medicine Inc Stock (PRME) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-10-24 Initiated JMP Securities Mkt Outperform
May-20-24 Initiated H.C. Wainwright Buy
May-16-24 Upgrade Citigroup Neutral → Buy
Apr-22-24 Initiated Chardan Capital Markets Buy
Apr-08-24 Initiated TD Cowen Buy
Apr-03-24 Initiated Wedbush Outperform
Jan-16-24 Downgrade Stifel Buy → Hold
Dec-08-23 Initiated Citigroup Neutral
Oct-09-23 Initiated BMO Capital Markets Outperform
Jul-31-23 Initiated Guggenheim Buy
Apr-18-23 Initiated Stifel Buy
Nov-14-22 Initiated Goldman Neutral
Nov-14-22 Initiated JP Morgan Overweight
Nov-14-22 Initiated Jefferies Buy
Nov-14-22 Initiated Morgan Stanley Equal-Weight
View All

Prime Medicine Inc Stock (PRME) Latest News

pulisher
02:22 AM

Chardan Capital Forecasts Prime Medicine FY2025 Earnings - Defense World

02:22 AM
pulisher
Mar 12, 2025

Prime Medicine’s SWOT analysis: gene editing firm’s stock poised for pivotal year - Investing.com

Mar 12, 2025
pulisher
Mar 10, 2025

Prime Medicine Inc (PRME)’s Market Momentum: Closing Strong at 2.40, Up 4.35 - The Dwinnex

Mar 10, 2025
pulisher
Mar 10, 2025

Is Prime Medicine Inc (NASDAQ: PRME) A Great Stock To Invest In? - Stocks Register

Mar 10, 2025
pulisher
Mar 10, 2025

Oppenheimer & Co. Inc. Decreases Stake in Prime Medicine, Inc. (NYSE:PRME) - Defense World

Mar 10, 2025
pulisher
Mar 07, 2025

HC Wainwright Expects Increased Earnings for Prime Medicine - Defense World

Mar 07, 2025
pulisher
Mar 04, 2025

Citizens JMP maintains $10 target on Prime Medicine stock - Investing.com India

Mar 04, 2025
pulisher
Mar 04, 2025

Prime Medicine’s (PRME) Buy Rating Reaffirmed at HC Wainwright - Defense World

Mar 04, 2025
pulisher
Mar 04, 2025

Prime Medicine (NYSE:PRME) Given “Buy” Rating at Chardan Capital - Defense World

Mar 04, 2025
pulisher
Mar 04, 2025

Prime Medicine’s Advancements and Financial Strength Support Buy Rating Amid Promising Developments in Gene Editing and Rare Diseases - TipRanks

Mar 04, 2025
pulisher
Mar 03, 2025

Prime Medicine, Inc.: Promising Gene Editing Developments and Strong Financial Position Justify Buy Rating - TipRanks

Mar 03, 2025
pulisher
Mar 03, 2025

Prime Medicine’s (PRME) “Outperform” Rating Reiterated at Wedbush - Defense World

Mar 03, 2025
pulisher
Mar 01, 2025

ARK Investment Management LLC Reduces Stock Holdings in Prime Medicine, Inc. (NYSE:PRME) - MarketBeat

Mar 01, 2025
pulisher
Feb 28, 2025

Prime Medicine Reports 2024 Financial Results and Progress - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Prime Medicine, Inc. SEC 10-K Report - TradingView

Feb 28, 2025
pulisher
Feb 28, 2025

Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates - The Manila Times

Feb 28, 2025
pulisher
Feb 28, 2025

Can Prime Medicine's $204M Cash Boost Fuel Its Gene Editing Breakthrough? Clinical Data Coming in 2025 - StockTitan

Feb 28, 2025
pulisher
Feb 28, 2025

Prime Medicine (NYSE:PRME) vs. Bio-Techne (NASDAQ:TECH) Critical Analysis - Defense World

Feb 28, 2025
pulisher
Feb 27, 2025

News: CMN Weekly (28 February 2025)Your Weekly CRISPR Medicine News - CRISPR Medicine News

Feb 27, 2025
pulisher
Feb 25, 2025

Contrasting Prime Medicine (NYSE:PRME) and Achilles Therapeutics (NASDAQ:ACHL) - Defense World

Feb 25, 2025
pulisher
Feb 24, 2025

Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference - The Manila Times

Feb 24, 2025
pulisher
Feb 24, 2025

Prime Medicine, Inc. (NYSE:PRME) Given Consensus Recommendation of “Buy” by Brokerages - Defense World

Feb 24, 2025
pulisher
Feb 19, 2025

Comparing Qiagen (NYSE:QGEN) & Prime Medicine (NYSE:PRME) - Defense World

Feb 19, 2025
pulisher
Feb 16, 2025

Sumitomo Mitsui Trust Group Inc. Has $9.02 Million Stock Holdings in Prime Medicine, Inc. (NYSE:PRME) - MarketBeat

Feb 16, 2025
pulisher
Feb 14, 2025

Prime Medicine (NYSE:PRME) Upgraded at StockNews.com - MarketBeat

Feb 14, 2025
pulisher
Feb 11, 2025

Prime Medicine (NYSE:PRME) Raised to Sell at StockNews.com - Defense World

Feb 11, 2025
pulisher
Feb 10, 2025

Analysts review Prime Medicine Inc’s rating - Knox Daily

Feb 10, 2025
pulisher
Feb 10, 2025

Closing Figures: Prime Medicine Inc (PRME)’s Negative Finish at 2.47, Down -1.98 - The Dwinnex

Feb 10, 2025
pulisher
Feb 06, 2025

There is no way Prime Medicine Inc (PRME) can keep these numbers up - SETE News

Feb 06, 2025
pulisher
Feb 06, 2025

Prime Medicine, Inc. (NYSE:PRME) Receives $13.13 Average PT from Brokerages - Armenian Reporter

Feb 06, 2025
pulisher
Feb 05, 2025

Prime Medicine: Gene Editing Company, Risky Investment (NASDAQ:PRME) - Seeking Alpha

Feb 05, 2025
pulisher
Feb 04, 2025

Metric Analysis: Prime Medicine Inc (PRME)’s Key Ratios in the Limelight - The Dwinnex

Feb 04, 2025
pulisher
Feb 02, 2025

Analysts Set Prime Medicine, Inc. (NYSE:PRME) Price Target at $13.13 - MarketBeat

Feb 02, 2025
pulisher
Feb 02, 2025

Brokerages Set Prime Medicine, Inc. (NYSE:PRME) PT at $13.13 - Defense World

Feb 02, 2025
pulisher
Feb 01, 2025

Nisa Investment Advisors LLC Buys 12,507 Shares of Prime Medicine, Inc. (NYSE:PRME) - Defense World

Feb 01, 2025
pulisher
Jan 31, 2025

Layoff Tracker: Thermo Fisher to Cut 300 People Across 2 Massachusetts Sites - BioSpace

Jan 31, 2025
pulisher
Jan 30, 2025

Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm -January 30, 2025 at 12:27 pm EST - Marketscreener.com

Jan 30, 2025
pulisher
Jan 30, 2025

Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm - PR Newswire

Jan 30, 2025
pulisher
Jan 29, 2025

PBM Prime Therapeutics to Pay $10 Million Antitrust Case Over Price-Fixing Scheme with Express Scripts, Inc. - Policy & Medicine

Jan 29, 2025
pulisher
Jan 21, 2025

In Vivo’s Deal Of The Year: Cast Your Vote! - Citeline News & Insights

Jan 21, 2025
pulisher
Jan 20, 2025

Barclays PLC Increases Stock Holdings in Prime Medicine, Inc. (NYSE:PRME) - Defense World

Jan 20, 2025
pulisher
Jan 15, 2025

StockNews.com Upgrades Prime Medicine (NYSE:PRME) to Sell - MarketBeat

Jan 15, 2025
pulisher
Jan 15, 2025

StockNews.com Upgrades Prime Medicine (NYSE:PRME) to “Sell” - Defense World

Jan 15, 2025
pulisher
Jan 14, 2025

Alliance for Regenerative Medicine: Field growing, cost still an issue - BioWorld Online

Jan 14, 2025
pulisher
Jan 13, 2025

Prime Medicine Advances Gene Editing and Trials - TipRanks

Jan 13, 2025
pulisher
Jan 13, 2025

Jane Street Group LLC Trims Stock Position in Prime Medicine, Inc. (NYSE:PRME) - Defense World

Jan 13, 2025
pulisher
Jan 08, 2025

Prime Medicine, Inc. (NYSE:PRME) Receives $12.67 Average Price Target from Analysts - Defense World

Jan 08, 2025

Prime Medicine Inc Stock (PRME) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$75.07
price up icon 1.39%
$305.39
price down icon 0.55%
$19.19
price down icon 3.62%
$32.68
price down icon 0.52%
$97.47
price down icon 2.84%
biotechnology ONC
$254.57
price up icon 1.89%
Cap:     |  Volume (24h):